Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05565937
Other study ID # 914
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 12, 2023
Est. completion date February 28, 2024

Study information

Verified date June 2023
Source Bausch & Lomb Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 340 participants (680 eyes) will be enrolled in this three-month, two-arm, 1:1 randomized, parallel-group, bilateral, double-masked study at approximately 22 investigative sites in the United States. Participants will be required to wear dispensed study lenses on a daily wear basis for three months with scheduled in-office replacement of study lenses at the 1-Month and 2-Month Follow-Up Visits.


Recruitment information / eligibility

Status Completed
Enrollment 296
Est. completion date February 28, 2024
Est. primary completion date February 28, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Is of legal age (at least 18) on the date the Informed Consent Form (ICF) is signed 2. Is able to read, understand, and provide written informed consent on the Institutional Review Board (IRB)/Ethics Committee (EC) approved ICF and provide authorization as appropriate for local privacy regulations 3. Is a habitual wearer (at least 3 months) 4. Has typically cleaned and disinfected their pre-study contact lenses daily 5. Must have spectacle correctable distance visual acuity through spherocylindrical refraction to 40 letters (0.14 logarithm of the minimal angle of resolution (logMAR) or better in each eye, at 2 meters distance with high contrast chart 6. Has clear central corneas and is free of any anterior segment disorders 7. Is a habitual user of a lens care product for cleaning, disinfecting, and storage of lenses 8. Requires lens correction in both eyes 9. Wears the same manufacturer and brand of lens in both eyes 10. Agrees to wear study lenses on a daily wear basis for approximately three months 11. Is willing and able to comply with all treatment and follow-up/study procedures. Exclusion Criteria: 1. Is currently using a hydrogen-peroxide cleaning and disinfecting solution 2. Participated in any drug or device clinical investigation within 30 days prior to entry into this study 3. Is a female of childbearing potential (those who are not surgically sterilized or postmenopausal) if they meet any one of the following conditions: - they are currently pregnant - they plan to become pregnant during the study - they are breastfeeding 4. Has worn gas permeable (GP) lenses within the last 30 days 5. Has worn polymethylmethacrylate (PMMA) lenses within the last three months 6. Has typically worn their pre-study contact lenses on an extended wear basis, sleeping in their lenses one night or more per week, during the last year 7. Has any systemic disease currently affecting ocular health or which in the Investigator's opinion may have an effect on ocular health during the course of the study 8. Subjects with an active ocular disease, or who are using any ocular medication. 9. Is using any medications that will, in the Investigator's opinion, affect ocular physiology or lens performance 10. Currently wears monovision, multifocal, or toric contact lenses 11. Has ocular astigmatism of 1.00D or greater in either eye 12. Has anisometropia (spherical equivalent) of greater than 2.00D 13. Has any grade 2 or greater finding during the slit-lamp examination (refer to Appendix B for Methods of Clinical Evaluation) 14. Has corneal infiltrates, of ANY GRADE 15. Has any "Present" ungraded finding during the slit-lamp examination (refer to Appendix B for Methods of Clinical Evaluation) that, in the Investigator's judgment, interferes with contact lens wear. 16. Has typically worn their pr-study control lenses on an extended wear bases, sleeping on their lenses one night or more per week, during the last year. 17. Is aphakic 18. Is amblyopic 19. Has had any corneal surgery (e.g., refractive surgery) 20. Is allergic to any component in the study care products. 21. Is an employee of any of the study investigative sites or a family member of an employee of the investigative site, including family members living outside of the employee's household 22. Is an Ophthalmologist, an Optometrist, an Optician, or an Ophthalmic Assistant/Technician, or currently resides with a person with any of these specialties 23. Is an employee of a manufacturer of contact lenses or contact lens care products (e.g., Alcon, Bausch + Lomb, Ciba Vision, CooperVision, Vistakon, Johnson & Johnson, etc.) or currently resides with a person employed by any of these manufacturers.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BL-3100-NBR03 multi-purpose solution
BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
renu® Advanced Formula multi-purpose solution
renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses

Locations

Country Name City State
United States The Eyecare Studio, LLC Decatur Georgia
United States Chester T Roe III MD Prof LLC Denver Colorado
United States Pearle Vision Jacksonville Florida
United States Spectrum Eyecare Jamestown New York
United States Total Eye Care, PA Memphis Tennessee
United States Optometric Physicians of Middle Tennessee Nashville Tennessee
United States Kannarr EyeCare Pittsburg Kansas
United States Casco Bay EyeCare Portland Maine
United States Oculus Research Raleigh North Carolina
United States Koetting Associates Saint Louis Missouri
United States Eric White OD Inc San Diego California
United States Lee & Woo Optometry San Francisco California
United States Golden Vision Sarasota Florida
United States Saccco Eye Group Vestal New York

Sponsors (1)

Lead Sponsor Collaborator
Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall comfort averaged over all scheduled follow-up visits Overall comfort will be assessed for each eye on a scale from 0 to 100, with 100 denoting the most favorable response 3 months
Primary Vision averaged over all scheduled follow-up visits Vision will be assessed for each eye on a scale from 0 to 100, with 100 denoting the most favorable response 3 months
Primary The proportion of eyes with a maximum degree of front surface deposits grade of < 2 over all scheduled follow-up visits The degree of front surface deposits will be graded for each eye as 0, 1, 2, 3, or 4. 3 months
Primary The proportion of eyes with any slit-lamp findings greater than Grade 2 over all follow-up visits. Graded slit-lamp findings will be assessed for each eye using Grades 0 through 4. 3 months
See also
  Status Clinical Trial Phase
Completed NCT06098937 - Kalifilcon A Toric Compared to Commercially Available Lenses N/A
Completed NCT06053736 - 1-Week Dispensing Evaluation of REVIVEā„¢ Toric Soft Contact Lenses N/A
Completed NCT04085328 - Assessment of an Investigational Frequent Replacement Silicone Hydrogel Lens N/A
Completed NCT01484028 - Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens N/A
Completed NCT01484054 - Dispensing Evaluation of Subjective Comfort, Vision, and Handling of a New Lens Compared to a Marketed Lens N/A
Completed NCT05765227 - Clinical Evaluation of a Manufacturing Process for a Frequent Replacement Silicone Hydrogel Multifocal Contact Lens N/A
Completed NCT05790928 - Air Optix Night and Day Aqua (AONDA) Retrospective Study 1
Completed NCT04013789 - Comparison of Two Daily Disposable Lenses N/A